Utilization of luteinizing hormone-releasing hormone agonist in pulmonary leiomyomatosis.
A patient presenting a recurrent episode of pulmonary leiomyomatosis has been treated with the LH-RH agonist buserelin at a dosage of 200 micrograms tid SC for 7 days, then 500 micrograms SC daily for a total period of 6 months. Basal serum E2 was suppressed during treatment and varied between 62 and 180 pmol/ml (mean, 129.4 +/- 14.5). Pulmonary symptoms completely disappeared during treatment, but no objective regression of the pulmonary lesions was observed. Because of the uncertainty of response of benign metastasizing leiomyomas to castration and because of the reversibility of the medical treatment, LH-RH agonist may be preferred to surgical castration in this pathology.
D000236:Adenoma / Q000556:secondary; D000310:Adrenal Gland Neoplasms / Q000556:secondary; D000328:Adult; D002064:Buserelin / Q000627:therapeutic use*; D004417:Dyspnea; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy / Q000556:secondary*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D010052:Ovariectomy; D010146:Pain; D014594:Uterine Neoplasms / Q000473:pathology / Q000601:surgery
D004958:Estradiol; D002064:Buserelin